A risk-benefit assessment of the levonorgestrel-releasing intrauterine system

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
F Sturridge, J Guillebaud

Abstract

The levonorgestrel-releasing intrauterine system (LNG-IUS), has been developed by Leiras Pharmaceuticals, Turku, Finland. It is a new systemic hormonal contraceptive that releases levonorgestrel 20 micrograms every 24 hours. The device provides fertility control comparable with that of female sterilisation, complete reversibility and convenience, and has an excellent tolerability record. The low dosage of levonorgestrel released by its unique delivery system ensures minimal hormone-related systemic adverse effects, which tend to be in the category of 'nuisance' rather than hazardous, and gradually diminish after the first few months of use. In some respects, the contraceptive characteristics of the LNG-IUS have over-shadowed a substantial range of noncontraceptive beneficial effects that are rarely seen with inert or copper-releasing intrauterine contraceptive devices (IUDs), and have important and positive gynaecological and public health implications. This applies particularly to the profound reduction in duration and quantity of menstrual bleeding, and alleviation of dysmenorrhoea, which are associated with the use of the device. Recent studies have shown that the LNG-IUS is effective in preventing endometrial proliferation ...Continue Reading

Citations

Feb 19, 2004·Contraception·Xiaoming CaoDirk Wildemeersch
Jun 1, 2002·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Dirk Wildemeersch, E Schacht
Feb 24, 2001·BJOG : an International Journal of Obstetrics and Gynaecology·A StewartW Phillips
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Peter DammKresten Rubeck Petersen
Aug 19, 2000·BMJ : British Medical Journal·B Donovan
Mar 14, 2001·The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception·D Wildemeersch, E Schacht
Mar 14, 2001·The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception·D WildemeerschH Van Kets
Feb 19, 2002·The European Journal of Contraception & Reproductive Health Care : the Official Journal of the European Society of Contraception·D WildemeerschP Wildemeersch
Jan 5, 2011·Journal of Minimally Invasive Gynecology·George A VilosAngelos G Vilos
Oct 20, 2010·Journal of Minimally Invasive Gynecology·George A VilosJennifer Marks
Jan 25, 2005·BJOG : an International Journal of Obstetrics and Gynaecology·C E C KingmanD L Economides
Jun 12, 2004·The Australian & New Zealand Journal of Obstetrics & Gynaecology·Bruno Radesic, Anil Sharma
Nov 9, 2005·Fertility and Sterility·Rezan A KadirJenny Goudemand
Jun 6, 2013·The Cochrane Database of Systematic Reviews·Li LuoNeil Sidell
Dec 7, 2018·The Cochrane Database of Systematic Reviews·Li LuoNeil Sidell
Jan 19, 2008·The Journal of Family Planning and Reproductive Health Care·Andrea PilkingtonDavid W Polson
Jul 22, 2006·The Journal of Family Planning and Reproductive Health Care·Elena Valarche
Dec 14, 2004·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Tiina Backman
Mar 8, 2016·Expert Opinion on Drug Delivery·Dirk WildemeerschThomas Hasskamp
Nov 7, 2013·The Journal of Clinical Endocrinology and Metabolism·Ian BlumerYariv Yogev
May 29, 2021·Clinical Breast Cancer·Fabio R SilvaMaria Inês da Rosa
Oct 2, 2021·Experimental and Therapeutic Medicine·Aurelian Mihai GhitaAna Cristina Ghita

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.